Table 3.

Comparison of biomarker expression between placebo and tamoxifen groups in overall follow-up period

ParameterTamoxifen (n = 79)Placebo (n = 100)P
ER
 Median H-score (IQR)86.4 (0–163.9)150.8 (73.6–184.6)0.001
ER+
 Median H-score (IQR)135.8 (84.0–182.2)164 (110.6–191.40.053
 Positive54 (68%)85 (85%)
 Negative25 (32%)15 (15%)0.008
PgR
 Median H-score (IQR)52.9 (0–153.7)87.2 (1.3–168.4)0.180
 Median H-score (IQR)110.7 (58.8–184.5)115.9 (66.9–180.6)0.643
 Positive50 (63%)76 (76%)
 Negative29 (37%)24 (24%)0.064
ER/PgR
 ER+/PgR+49 (62%)76 (76%)0.800a
Status
 ER+/PgR5 (6%)9 (9%)
 ER/PgR24 (30%)15 (15%)
 ER/PgR+1 (1%)0
Ki67
 Median % + (IQR)10.2 (5.1–34.5)10.2 (4.2–18.3)0.280
HER2
 Positive12 (15%)10 (10%)
 Negative67 (85%)90 (90%)0.294
EGFR
 Positive15 (19%)12 (12%)
 Negative64 (81%)88 (88%)0.205
  • aP value relates to the difference between PgR+ and PgR among the ER+ by χ2 test.